- Home
- ETON vs MOLN Comparison
ETON vs MOLN Comparison
Compare ETON & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- MOLN
- Stock Information
- Founded
- ETON 2017
- MOLN 2004
- Country
- ETON United States
- MOLN Switzerland
- Employees
- ETON N/A
- MOLN N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- MOLN
- Sector
- ETON Health Care
- MOLN
- Exchange
- ETON Nasdaq
- MOLN Nasdaq
- Market Cap
- ETON 199.5M
- MOLN 214.4M
- IPO Year
- ETON 2018
- MOLN 2021
- Fundamental
- Price
- ETON $11.91
- MOLN $5.31
- Analyst Decision
- ETON Strong Buy
- MOLN
- Analyst Count
- ETON 2
- MOLN 0
- Target Price
- ETON $15.00
- MOLN N/A
- AVG Volume (30 Days)
- ETON 236.0K
- MOLN 26.7K
- Earning Date
- ETON 11-12-2024
- MOLN 08-26-2024
- Dividend Yield
- ETON N/A
- MOLN N/A
- EPS Growth
- ETON N/A
- MOLN N/A
- EPS
- ETON N/A
- MOLN N/A
- Revenue
- ETON $34,677,000.00
- MOLN $7,105,397.00
- Revenue This Year
- ETON $23.05
- MOLN N/A
- Revenue Next Year
- ETON $81.27
- MOLN $29.41
- P/E Ratio
- ETON N/A
- MOLN N/A
- Revenue Growth
- ETON 5.64
- MOLN N/A
- 52 Week Low
- ETON $3.03
- MOLN $3.32
- 52 Week High
- ETON $13.98
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- ETON 54.63
- MOLN 43.84
- Support Level
- ETON $11.64
- MOLN $5.26
- Resistance Level
- ETON $13.01
- MOLN $5.65
- Average True Range (ATR)
- ETON 0.82
- MOLN 0.20
- MACD
- ETON -0.16
- MOLN -0.04
- Stochastic Oscillator
- ETON 11.54
- MOLN 6.85
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.